
Schrodinger (SDGR) Stock Forecast & Price Target
Schrodinger (SDGR) Analyst Ratings
Bulls say
Schrodinger Inc. reported strong fourth-quarter software results, with software revenues exceeding consensus expectations by approximately 2% and reflecting a significant year-over-year growth of around 44%. The company's total annual contract value (ACV) rose by 9.7% to $154.2 million, while the retention rate for high-value customers remained robust at 98%, with an increase in the number of customers generating at least $1 million in ACV. Additionally, software gross margins expanded to an impressive 87%, indicating effective cost management and profitability within the software segment.
Bears say
Schrodinger Inc. has issued a lowered guidance for drug discovery revenue, projecting $30 million to $35 million for FY24, which marks a decline from the previous year's revenue of $45.4 million. The company reported a significant year-over-year decrease of 38.9% in drug discovery revenues for Q4 2023, coming in at $5.5 million, which was substantially below both internal expectations and consensus estimates. Furthermore, the company’s software revenue growth forecast for FY24 of 6-13% is below market expectations of 18%, combined with higher than anticipated R&D and G&A expenses, pointing to persistent financial pressures and a potentially challenging outlook ahead.
This aggregate rating is based on analysts' research of Schrodinger and is not a guaranteed prediction by Public.com or investment advice.
Schrodinger (SDGR) Analyst Forecast & Price Prediction
Start investing in Schrodinger (SDGR)
Order type
Buy in
Order amount
Est. shares
0 shares